Frontiers in psychology · 2025
Clinical application of abdominal breathing training and evaluation of physical and mental benefits in anxiety patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chai Jiajin, Li Shikun, He Li, Yang Jiayuan, Wu Ting, Ou Kunyang, Chen Xichen, Ma Kaicheng, Zhao Shouping
Аннотация
BACKGROUND: Anxiety disorders represent highly prevalent mental health conditions globally (lifetime prevalence: ~7-14%). Current pharmacological treatments carry risks of dependence and metabolic side effects, while psychological therapies face accessibility limitations. There is an urgent need to develop safe, accessible non-pharmacological interventions. This single-blind randomized controlled trial systematically evaluated the efficacy and sustainability of an 8-week standardized abdominal breathing training program in alleviating anxiety symptoms and modulating autonomic nervous function in patients with anxiety disorders.
METHODS: A total of 120 outpatient participants (aged 18-65 years) meeting ICD-10 diagnostic criteria for Generalized Anxiety Disorder were recruited. Participants were randomly assigned to either an intervention group (abdominal breathing training, n = 60) or a control group (treatment-as-usual, n = 60). The intervention group received professionally supervised training consisting of 3-4 daily sessions of 10-15 min each (inhale:exhale ratio = 1:2; inhalation 3-5 s/exhalation 5-7 s). Adherence was monitored via respiratory sensors (mean adherence rate: 92.4%). Assessments using the Self-Rating Anxiety Scale (SAS) and physiological measurements-including heart rate (HR), respiratory rate (RR), blood pressure (BP), and heart rate variability (HRV-LF/HF ratio)-were conducted at baseline, post-intervention (8 weeks), and at 4-week follow-up (intervention group only).
RESULTS: Anxiety symptom improvement: Two-way repeated measures ANOVA revealed a significant group × time interaction effect on SAS scores (p < 0.05). Post-intervention, the intervention group exhibited a significant reduction in SAS scores compared to baseline (67.57 ± 8.88 vs. 71.80 ± 3.99, p < 0.001), reflecting a 5.9% decrease, and scores were significantly lower than the control group (70.43 ± 4.33, p = 0.027). At 4-week follow-up, despite a slight rebound, SAS scores in the intervention group remained significantly below baseline (68.57 ± 8.11, p < 0.05). Physiological optimization: For physiological indicators, significant group × time interaction effects were observed (all p < 0.05). Post-intervention, the intervention group showed significant reductions in heart rate (77.08 ± 10.30 vs. 83.37 ± 9.67 bpm), respiratory rate (17.37 ± 1.78 vs. 18.60 ± 1.83 breaths/min), systolic blood pressure (114.12 ± 11.97 vs. 122.63 ± 12.18 mmHg), and diastolic blood pressure (74.40 ± 6.75 vs. 80.28 ± 7.58 mmHg) (all p < 0.05). Concurrently, the HRV-LF/HF ratio increased significantly (p = 0.008).
CONCLUSION: Standardized abdominal breathing training significantly alleviates anxiety symptoms (effect size Cohen's d = 0.61) and induces sustained physiological improvements in autonomic regulation (effects maintained 4 weeks post-intervention). As a cost-free, non-pharmacological intervention devoid of adverse effects, it provides an effective adjunctive treatment option for anxiety disorders, particularly benefiting medically underserved populations and individuals with medication intolerance, suggesting significant clinical potential.
METHODS: A total of 120 outpatient participants (aged 18-65 years) meeting ICD-10 diagnostic criteria for Generalized Anxiety Disorder were recruited. Participants were randomly assigned to either an intervention group (abdominal breathing training, n = 60) or a control group (treatment-as-usual, n = 60). The intervention group received professionally supervised training consisting of 3-4 daily sessions of 10-15 min each (inhale:exhale ratio = 1:2; inhalation 3-5 s/exhalation 5-7 s). Adherence was monitored via respiratory sensors (mean adherence rate: 92.4%). Assessments using the Self-Rating Anxiety Scale (SAS) and physiological measurements-including heart rate (HR), respiratory rate (RR), blood pressure (BP), and heart rate variability (HRV-LF/HF ratio)-were conducted at baseline, post-intervention (8 weeks), and at 4-week follow-up (intervention group only).
RESULTS: Anxiety symptom improvement: Two-way repeated measures ANOVA revealed a significant group × time interaction effect on SAS scores (p < 0.05). Post-intervention, the intervention group exhibited a significant reduction in SAS scores compared to baseline (67.57 ± 8.88 vs. 71.80 ± 3.99, p < 0.001), reflecting a 5.9% decrease, and scores were significantly lower than the control group (70.43 ± 4.33, p = 0.027). At 4-week follow-up, despite a slight rebound, SAS scores in the intervention group remained significantly below baseline (68.57 ± 8.11, p < 0.05). Physiological optimization: For physiological indicators, significant group × time interaction effects were observed (all p < 0.05). Post-intervention, the intervention group showed significant reductions in heart rate (77.08 ± 10.30 vs. 83.37 ± 9.67 bpm), respiratory rate (17.37 ± 1.78 vs. 18.60 ± 1.83 breaths/min), systolic blood pressure (114.12 ± 11.97 vs. 122.63 ± 12.18 mmHg), and diastolic blood pressure (74.40 ± 6.75 vs. 80.28 ± 7.58 mmHg) (all p < 0.05). Concurrently, the HRV-LF/HF ratio increased significantly (p = 0.008).
CONCLUSION: Standardized abdominal breathing training significantly alleviates anxiety symptoms (effect size Cohen's d = 0.61) and induces sustained physiological improvements in autonomic regulation (effects maintained 4 weeks post-intervention). As a cost-free, non-pharmacological intervention devoid of adverse effects, it provides an effective adjunctive treatment option for anxiety disorders, particularly benefiting medically underserved populations and individuals with medication intolerance, suggesting significant clinical potential.